Kamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing and Distribution of a Plasma-Derived Anti-SARS-CoV-2 (COVID-19) Polyclonal Immunoglobulin Prod...
Kamada Ltd. - Ordinary Shares (KMDA)
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
kamada.com/investors.php
Company Research
Source: GlobeNewswire
Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s ResponsibilityKedrion is Responsible for the Collection and Supply of Plasma from Convalescent COVID-19 Patients, Support of Clinical Development and Distribution in the U.S., Europe, Australia, and S. Korea REHOVOT, Israel and CASTELVECCHIO PASCOLI, Italy, April 27, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA) and Kedrion Biopharma, two prominent bio-pharmaceutical companies specialized in plasma-derived protein therapeutics, today announced a global collaboration for the development, manufacturing and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients. The announcement follows separate previous reports by each of the two entities in connection with initiation of development programs for such pr
Show less
Read more
Impact Snapshot
Event Time:
KMDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KMDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KMDA alerts
High impacting Kamada Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KMDA
News
- Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements [Yahoo! Finance]Yahoo! Finance
- Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability GrowthGlobeNewswire
- Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result [Yahoo! Finance]Yahoo! Finance
- Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney TransplantationGlobeNewswire
- Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025GlobeNewswire
KMDA
Earnings
- 11/10/25 - Miss
KMDA
Sec Filings
- 12/2/25 - Form 6-K/A
- 11/10/25 - Form 6-K
- 11/4/25 - Form 6-K
- KMDA's page on the SEC website